NCT06953089View on ClinicalTrials.gov

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

492

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

June 30, 2030

Conditions
Solid Tumors
Interventions
DRUG

DB-1311/BNT324

Administered I.V.

DRUG

BNT327

Administered I.V.

DRUG

DB-1305/BNT325

Administered I.V.

Trial Locations (30)

0

RECRUITING

TWN01-0, Taipei

2060

RECRUITING

AUS07-0, North Sydney

4217

RECRUITING

AUS06-0, Benowa

4575

RECRUITING

AUS04-0, Birtinya

5000

RECRUITING

AUS05-0, Adelaide

10032

RECRUITING

USA04-0, New York

15232

RECRUITING

USA02-0, Pittsburgh

22031

RECRUITING

USA05-0, Virginia Beach

23561

RECRUITING

TWN02-0, Taipei

29425

RECRUITING

USA03-0, Charleston

80033

RECRUITING

USA01-0, Wheat Ridge

90025

RECRUITING

USA06-0, Los Angeles

99208

RECRUITING

USA08-0, Florida City

RECRUITING

USA07-0, Spokane

100021

RECRUITING

CHN02-0, Beijing

100032

RECRUITING

CHN13-0, Beijing

100142

RECRUITING

CHN23-0, Beijing

110042

RECRUITING

CHN35-0, Shenyang

200032

RECRUITING

CHN04-0, Shanghai

200120

RECRUITING

CHN01-0, Shanghai

221000

RECRUITING

CHN16-0, Xuzhou

410013

RECRUITING

CHN11-0, Changsha

430014

RECRUITING

CHN04-0, Hubei

430079

RECRUITING

CHN34-0, Wuhan

450008

RECRUITING

CHN06-0, Henan

453100

RECRUITING

CHN12-0, Xinxiang

523000

RECRUITING

CHN17-0, Dongguan

610041

RECRUITING

CHN24-0, Chengdu

710061

RECRUITING

CHN25-0, Xi'an

00000

RECRUITING

CHN26-0, Wuhan

Sponsors

Collaborators (1)

BioNTech SE
All Listed Sponsors
collaborator

BioNTech SE

INDUSTRY

lead

DualityBio Inc.

INDUSTRY